GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Cyclically Adjusted Price-to-FCF

Jazz Pharmaceuticals (FRA:J7Z) Cyclically Adjusted Price-to-FCF : 10.51 (As of May. 01, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Cyclically Adjusted Price-to-FCF?

As of today (2024-05-01), Jazz Pharmaceuticals's current share price is €103.65. Jazz Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was €9.86. Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 10.51.

The historical rank and industry rank for Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

FRA:J7Z' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 10.01   Med: 24.85   Max: 484.64
Current: 10.13

During the past years, Jazz Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 484.64. The lowest was 10.01. And the median was 24.85.

FRA:J7Z's Cyclically Adjusted Price-to-FCF is ranked better than
95.15% of 103 companies
in the Biotechnology industry
Industry Median: 56.13 vs FRA:J7Z: 10.13

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted free cash flow per share data for the three months ended in Dec. 2023 was €1.833. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €9.86 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jazz Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Jazz Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.40 24.14 15.68 16.55 11.24

Jazz Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.55 14.47 11.62 11.83 11.24

Competitive Comparison of Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Jazz Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=103.65/9.86
=10.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Jazz Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.833/120.1096*120.1096
=1.833

Current CPI (Dec. 2023) = 120.1096.

Jazz Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.739 100.573 -0.883
201406 0.729 100.773 0.869
201409 0.576 100.474 0.689
201412 1.351 99.576 1.630
201503 1.205 99.975 1.448
201506 1.801 100.573 2.151
201509 2.397 100.274 2.871
201512 1.698 99.676 2.046
201603 2.014 99.676 2.427
201606 -0.381 101.072 -0.453
201609 1.667 100.274 1.997
201612 2.787 99.676 3.358
201703 2.460 100.374 2.944
201706 1.809 100.673 2.158
201709 1.441 100.474 1.723
201712 2.592 100.075 3.111
201803 2.124 100.573 2.537
201806 1.069 101.072 1.270
201809 3.014 101.371 3.571
201812 3.099 100.773 3.694
201903 2.107 101.670 2.489
201906 1.652 102.168 1.942
201909 4.235 102.268 4.974
201912 1.268 102.068 1.492
202003 0.855 102.367 1.003
202006 1.221 101.769 1.441
202009 3.692 101.072 4.387
202012 2.101 101.072 2.497
202103 4.069 102.367 4.774
202106 0.482 103.364 0.560
202109 3.438 104.859 3.938
202112 2.414 106.653 2.719
202203 2.478 109.245 2.724
202206 3.305 112.734 3.521
202209 6.803 113.431 7.204
202212 -0.635 115.425 -0.661
202303 3.999 117.618 4.084
202306 3.653 119.611 3.668
202309 3.981 120.708 3.961
202312 1.833 120.110 1.833

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Jazz Pharmaceuticals  (FRA:J7Z) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Jazz Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Jazz Pharmaceuticals (FRA:J7Z) Business Description

Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines